Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Orphanet Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol FLT4 contributors: mct - updated : 14-10-2014
HGNC name fms-related tyrosine kinase 4
HGNC id 3767
Corresponding disease
HLMN1 hereditary lymphedema I, type 1
PCLD primary congenital lymphedema
Location 5q35.3      Physical location : 180.028.506 - 180.076.624
Synonym name
  • vascular endothelial growth factor receptor 3 (VEGFR3)
  • tyrosine-protein kinase receptor FLT4
  • soluble VEGFR3 variant 1, 2, 3
  • vascular endothelial growth factor receptor 3
  • Synonym symbol(s) VEGFR3, PCL, FLT41, LMPH1A
    EC.number 2.7.10.1
    DNA
    TYPE functioning gene
    STRUCTURE 48.12 kb     30 Exon(s)
    10 Kb 5' upstream gene genomic sequence study
    regulatory sequence Promoter
    Binding site   enhancer
    text structure promoter control endothelial cell specific transcription of downstream reporter genes
    MAPPING cloned Y linked N status confirmed
    Map see ADRB2 , DRD1
    RNA
    TRANSCRIPTS type messenger
    identificationnb exonstypebpproduct
    ProteinkDaAAspecific expressionYearPubmed
    30 splicing 5857 152.63 1363 - 2001 11479678
  • a 32 exons variant
  • containing exon 1b (shorter than 1a)
  • lacking exon 30
  • 30 splicing 4534 145.6 1298 - 2001 11479678
  • a 30 exons variant
  • containing exon 1a (longer than 1b)
  • lacking C terminal domain from exon 31 to 33
  • - - - - - - 2013 23476047
  • truncated isoform, soluble
  • critical for corneal alymphaticity
  • binds and sequesters VEGFC, thereby blocking signaling through FLT4 and suppressing lymphangiogenesis induced by VEGFC
  • EXPRESSION
    Type restricted
       expressed in (based on citations)
    organ(s)
    SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
    Cardiovascularheart   highly
    Nervousbrainhindbraincerebellum   Homo sapiensFetal
     brainforebrain    Homo sapiensFetal
    Reproductivemale systemprostate  highly
    Respiratorylung   highly
    Skeleton      Homo sapiensAdult
     axial skeletonskullfacemandible  Homo sapiensFetal
    Urinarykidney   highly
    tissue
    SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
    Epithelialbarrier/lining   
    cells
    SystemCellPubmedSpeciesStageRna symbol
    Cardiovascularendothelial cell
    Skeletonosteoblast Homo sapiensAdult
    Skeletonosteoblast Homo sapiensFetal
    cell lineage
    cell lines
    fluid/secretion
    at STAGE
    physiological period embryo, pregnancy
    Text all vessels, placenta
    PROTEIN
    PHYSICAL PROPERTIES
    STRUCTURE
    motifs/domains
  • seven Ig-like extracellular domains
  • a transmembrane segment (1TM)
  • a cytoplasmic kinase domain
  • HOMOLOGY
    interspecies homolog to rattus Flt4 (86.72 pc)
    homolog to murine Flt4 (87.09 pc)
    Homologene
    FAMILY
  • protein kinase superfamily
  • Tyr protein kinase family
  • CSF-1/PDGF receptor subfamily
  • CATEGORY regulatory , protooncogene , signaling , receptor membrane
    SUBCELLULAR LOCALIZATION extracellular
        plasma membrane
        intracellular
    intracellular,cytoplasm
    intracellular,nucleus
    basic FUNCTION
  • receptor tyrosine kinase, class V, involved in lymphatic vascular function, regulating angiogenesis and vasculogenesis
  • crucial role for FLT4 in the regulation of sprouting in endothelial cells with low NOTCH1 signalling activity
  • its activity is pro-angiogenic in endothelial cells with low or no NOTCH1 signalling activity
  • directly interacts with phosphatidylinositol 3-kinase to regulate lymphangiogenesis
  • might represent a specific signal for ectomesenchymal lineage differentiation during early human development
  • FLT4 with its cognate ligand vascular endothelial growth factor C (VEGFC), is a major mediator of lymphangiogenesis
  • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS cardiovascular
    PATHWAY
    metabolism
    signaling
  • VEGFC/FLT4 signaling pathway is essential for lymphangiogenesis (the formation of lymphatic vessels from pre-existing vasculature) during embryonic development, tissue regeneration and tumor progression
  • a component
  • RSPO1-WNT-VEGFC-FLT4 signaling plays a crucial role as an endothelial-autonomous permissive cue for developmental angiogenesis
  • INTERACTION
    DNA
    RNA
    small molecule
    protein
  • VEGFC
  • FIGF (VEGFD)
  • interaction between NRP2 and FLT4 mediates proper lymphatic vessel sprouting in response to VEGFC
  • interacts with TMEM204 (TMEM204 attenuates the transcription factor CREB phosphorylation via FLT4 and KDR
  • macrophage-derived VEGFC activates FLT4 in tip cells to reinforce NOTCH signalling, which contributes to the phenotypic conversion of endothelial cells at fusion points of vessel sprouts
  • substantial DLL4 expression is maintained in the absence of KDR, while the FLT4 protein levels are strongly reduced
  • both NOTCH1 and KDR modulate FLT4 protein and activation levels independently and in opposite directions
  • interaction between COL18A1 short peptide and FLT4
  • VEGFC and its receptor FLT4 mediate lymphangiogenesis
  • CLEC14A acts in vascular homeostasis by fine-tuning KDR and FLT4 signaling in ECs, suggesting its relevance in the pathogenesis of angiogenesis-related human disorders
  • cell & other
    REGULATION
    ASSOCIATED DISORDERS
    corresponding disease(s) HLMN1 , PCLD
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    constitutional somatic mutation      
    in juvenile hemangioma
    tumoral     --over  
    in prostate cancer cells (increases the risk of biochemical recurrence in prostate cancer patients treated by radical prostatectomy)
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
    Therapy target
    SystemTypeDisorderPubmed
    cancerangiogenesis 
    blocking EFNB2 signaling in tumours might represent an intriguing strategy to interfere simultaneously with both KDR and FLT4 function that could be used as an alternative or combinatorial anti-angiogenic treatment for tumour therapy
    ANIMAL & CELL MODELS